Lung cancer risk in relation to mephenytoin hydroxylation activity

Pharmacogenetics. 1997 Apr;7(2):157-9. doi: 10.1097/00008571-199704000-00011.

Authors

S Benhamou¹, C Bouchardy, P Dayer

Affiliation

¹ Unit of Cancer Epidemiology (INSERM U351), Institut Gustave-Roussy, Villejuif, France.

PMID: 9170155
DOI: 10.1097/00008571-199704000-00011

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aryl Hydrocarbon Hydroxylases*
Carcinoma / enzymology*
Carcinoma / etiology
Carcinoma, Small Cell / enzymology
Carcinoma, Small Cell / etiology
Carcinoma, Squamous Cell / enzymology
Carcinoma, Squamous Cell / etiology
Case-Control Studies
Cytochrome P-450 CYP2C19
Cytochrome P-450 Enzyme System / metabolism*
Female
France / epidemiology
Humans
Hydroxylation
Lung Neoplasms / enzymology*
Lung Neoplasms / etiology
Male
Mephenytoin / metabolism*
Middle Aged
Mixed Function Oxygenases / metabolism*
Risk Factors
Smoking / adverse effects*
White People

Substances

Cytochrome P-450 Enzyme System
Mixed Function Oxygenases
Aryl Hydrocarbon Hydroxylases
CYP2C19 protein, human
Cytochrome P-450 CYP2C19
Mephenytoin